Zenas BioPharma, Inc.

NASDAQ:ZBIO

Biotechnology

Healthcare
$26.42 +3.46%

+$0.64 today

Market cap
$1.79B
Beta
-0.69
P/E (TTM)
-2.5
EPS (TTM)
-$7.64
52W Low $8.91High $44.60

Volume 0.48M

Average 0.71M

ZBIO EBITDA

Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.

Zenas BioPharma, Inc.NASDAQ: ZBIO

EBITDA · Q1 FY2026 · quarter ended Mar 2026

EBITDA remains negative

Q1 FY2026 EBITDA was -$74.35M, compared with -$33.76M a year earlier. Trailing-twelve-month EBITDA was -$408.44M.

Context

  • EBITDA amounted to 3704.3% of revenue in FY2025, up 575.9 pp from a year earlier.
  • EBITDA grew in size in 2 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether EBITDA reaches the consensus estimate from 4 analysts of -$269.7M (+27.2%) for the fiscal year ending Dec 2026, a step up from the -136.8% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$74.35M+67.7% QoQ
Last fiscal yearDec 2025
-$370.43M-136.8% YoY
LTMMar 2026
-$408.44M-151.5% YoY
EBITDA past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-120.3%-22.5%+97.8 pp
1 year-136.8%+27.2%+164.0 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA history

USD · from the income statement

Latest · FY2025
(370.43M) USD
Year-over-year change
-136.8%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA vs competitors

How ZBIO compares with its peers on the latest reported figures

  • ZBIO's LTM Mar 2026 EBITDA of -$408.44M is the 7th highest of the 8 companies compared; the peer median is -$156.57M.
  • Its year-over-year change of -151.5% is the lowest of 8, against a peer median of -17.1%.
ZBIO Competitors Peer median
EBITDA for ZBIO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
QTTBQ32 Bio Inc.LTM Mar 2026$22.15M +154.8%—41.2%
TLSATiziana Life Sciences LtdFY2025-$21.05M -26.7%——
ACRSAclaris Therapeutics, Inc.LTM Mar 2026-$70.61M -31.5%—843.9%
UPBUpstream Bio, Inc.LTM Mar 2026-$156.57M -98.0%—4713.1%
TRAXFirst Tracks Biotherapeutics IncFY2025-$178.45M +0.1%——
ANNXAnnexon, Inc.LTM Mar 2026-$193.41M -17.1%——
ZBIOZenas BioPharma, Inc.LTM Mar 2026-$408.44M -151.5%——
IMVTImmunovant, Inc.LTM Sep 2026-$509.88M -10.4%—7186.4%
Peer median (excluding ZBIO) -$156.57M-17.1%—2778.5%

Competitors are the stored peer set for ZBIO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue050M5M10M
Cost of Revenue61.69M0139.14M0
Gross Profit(61.69M)50M(134.14M)10M
Gross Margin—100.0%-2682.8%100.0%
Research & Development62.69M60.03M139.14M168.06M
Selling, General & Admin13.51M17.11M29.75M53.32M
Operating Expenses14.51M87.15M29.75M221.39M
Depreciation & Amortization78K113K137K56K
EBITDA(75.12M)(27.03M)(156.42M)(370.43M)
EBITDA Margin—-54.1%-3128.4%-3704.3%
Operating Income(76.2M)(37.15M)(163.89M)(211.39M)
Operating Margin—-74.3%-3277.8%-2113.8%
Interest Income00012.15M
Interest Expense0007.33M
Other Income / Expenses(43.08M)324K7.33M(166.43M)
Income Before Tax(119.28M)(36.82M)(156.56M)(377.82M)
Pre-Tax Margin—-73.6%-3131.2%-3778.2%
Income Tax Expense0301K429K(79K)
Net Income(119.28M)(37.12M)(156.99M)(377.74M)
Net Margin—-74.2%-3139.8%-3777.4%
EPS (Basic)(3.11)(0.97)(3.76)(8.44)
EPS (Diluted)(3.11)(0.97)(3.76)(8.44)
Weighted Avg Shares38.32M38.32M41.79M44.73M
Weighted Avg Shares (Diluted)38.32M38.32M41.79M44.73M

Zenas BioPharma, Inc.

NASDAQ:ZBIO

Intrinsic Alpha fair value

Locked

Current Price

$26.42

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.